Enzymotec Ltd. (NasdaqGS:ENZY) is seeking acquisitions. Ariel Katz, Enzymotec's President and Chief Executive Officer said, "Enzymotec remains in a financially strong position to support its growth initiatives. Even with the investments we committed to the business this year, our cash flow is solidly positive and our balance sheet continues to strengthen. We had a strong first quarter generating $3.3 million in operating cash flow and now have $79.2 million in cash, deposits and marketable securities on our balance sheet. As we look to deploy our cash judiciously with a growth strategy that includes potential acquisitions that are complementary to our business, the company is committed to its history of seeking prudent growth as well as our goal of creating value for our shareholders."